## Uros Milenkovic

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2749290/publications.pdf

Version: 2024-02-01

687363 713466 21 991 13 21 citations h-index g-index papers 21 21 21 813 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Single-cell Transcriptomics Uncover a Novel Role of Myeloid Cells and T-lymphocytes in the Fibrotic Microenvironment in Peyronie's Disease. European Urology Focus, 2022, 8, 814-828.	3.1	8
2	European Association of Urology Guidelines on Male Sexual and Reproductive Health: 2021 Update on Male Infertility. European Urology, 2021, 80, 603-620.	1.9	260
3	European Association of Urology Guidelines on Sexual and Reproductive Health—2021 Update: Male Sexual Dysfunction. European Urology, 2021, 80, 333-357.	1.9	360
4	Too good for CARMENA: criteria associated with long systemic therapy free intervals post cytoreductive nephrectomy for metastatic clear cell renal cell carcinoma. Scandinavian Journal of Urology, 2020, 54, 493-499.	1.0	12
5	The Cancer of the Bladder Risk Assessment (COBRA) score for estimating cancerâ€specific survival after radical cystectomy: external validation in a large biâ€institutional cohort. BJU International, 2020, 126, 704-714.	2.5	7
6	Evolving therapies for Peyronie's disease: how can we work towards new drugs?. Translational Andrology and Urology, 2020, 9, S284-S294.	1.4	2
7	The good, bad, and the ugly of regenerative therapies for erectile dysfunction. Translational Andrology and Urology, 2020, 9, S252-S261.	1.4	23
8	Comparison of postoperative complications of ileal conduits versus orthotopic neobladders. Translational Andrology and Urology, 2020, 9, 2541-2554.	1.4	15
9	Prognostic score predicts overall survival following complete urinary tract extirpation. Scandinavian Journal of Urology, 2020, 54, 70-79.	1.0	2
10	Pathophysiology and Future Therapeutic Perspectives for Resolving Fibrosis in Peyronie's Disease. Sexual Medicine Reviews, 2019, 7, 679-689.	2.9	33
11	Organ-sparing surgical and nonsurgical modalities in primary penile cancer treatment. Current Opinion in Urology, 2019, 29, 156-164.	1.8	19
12	Antifibrotic Synergy Between Phosphodiesterase Type 5 Inhibitors and Selective Oestrogen Receptor Modulators in Peyronie's Disease Models. European Urology, 2019, 75, 329-340.	1.9	34
13	The mechanisms and potential of stem cell therapy for penile fibrosis. Nature Reviews Urology, 2019, 16, 79-97.	3.8	42
14	Intratunical Injection of Human Adipose Tissue–Derived Stem Cells Restores Collagen III/I Ratio in a Rat Model of Chronic Peyronie's Disease. Sexual Medicine, 2019, 7, 94-103.	1.6	24
15	Simvastatin and the Rhoâ€kinase inhibitor Yâ€27632 prevent myofibroblast transformation in Peyronie's diseaseâ€derived fibroblasts via inhibition of YAP/TAZ nuclear translocation. BJU International, 2019, 123, 703-715.	2.5	22
16	Impact of neoadjuvant chemotherapy on short-term complications and survival following radical cystectomy. World Journal of Urology, 2019, 37, 1857-1866.	2.2	23
17	Intratunical injection of stromal vascular fraction prevents fibrosis in a rat model of Peyronie's disease. BJU International, 2019, 124, 342-348.	2.5	14
18	Clinical Efficacy of Injection and Mechanical Therapy for Peyronie's Disease: A Systematic Review of the Literature. European Urology, 2018, 74, 767-781.	1.9	45

#	Article	IF	CITATIONS
19	What Is the Future of Erectile Dysfunction Therapy?. Current Sexual Health Reports, 2018, 10, 169-176.	0.8	2
20	Stem Cells in Male Sexual Dysfunction: Are We Getting Somewhere?. Sexual Medicine Reviews, 2017, 5, 222-235.	2.9	34
21	The N-shaped orthotopic ileal neobladder: functional outcomes and complication rates in 119 patients. SpringerPlus, 2016, 5, 646.	1.2	10